Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free cash flow for the full fiscal year 2024.
Tilray Brands reported financial results on Tuesday for its third quarter ended Feb. 29, 2024, revealing $188.3 million in net revenue, representing a 30% year-over-year increase. Net loss decreased to $105 million in the third quarter compared to a net loss of $1.2 billion in the prior year quarter.
Tilray Brands shares dipped 22.2% to $2.0152 on Tuesday.
Here are some other stocks moving in today's mid-day session.
Gainers
- Laser Photonics Corporation (NASDAQ: LASE) shares climbed 168% to $3.82 after the company announced it secured an order for its LaserTower COMPACT marking and engraving system from L3Harris Technologies.
- BioSig Technologies, Inc. (NASDAQ: BSGM) shares surged 123% to $2.77 after jumping over 96% on Monday.
- Mobile Global Esports Inc. (NASDAQ: MGAM) jumped 100% to $0.2440.
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) climbed 62.4% to $9.60. The company announced a $130 million private placement financing.
- Selina Hospitality PLC (NASDAQ: SLNA) gained 47% to $0.0588. Selina management reaffirmed its confidence in its strategy and highlighted alignment with shareholders through equity ownership in the company.
- MediaCo Holding Inc. (NASDAQ: MDIA) shares jumped 37.3% to $4.15 after falling 22% on Monday. On April 4, an SEC filing showed Standard General L.P. reported a 95.2% stake in the company, as of April 1.
- Motorsport Games Inc. (NASDAQ: MSGM) surged 34% to $2.73.
- Rail Vision Ltd. (NASDAQ: RVSN) gained 29% to $2.02 after the company announced that it secured an order for its AI-powered Switch Yard System from a Class 1 freight rail company in North America.
- Anghami Inc. (NASDAQ: ANGH) surged 28.5% to $1.44.
- Biophytis S.A. (NASDAQ: BPTS) rose 24.9% to $0.3959 after reporting FY23 results.
- Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) climbed 21.1% to $5.45. Syros received Fast Track Designation from the FDA for tamibarotene for the treatment of newly ...
